1. Cardiogenic Shock

Quick Recap

Cardiovascular System, Protocol 2/12.

1. Definition

Cardiogenic shock (CS) = state of end-organ hypoperfusion and tissue hypoxia due to reduced cardiac output despite adequate intracardiac filling pressures (distinguishing it from hypovolemic shock).

Pooled trial definition: SBP <90 mmHg for >=30 min (or supportive intervention needed to maintain >90) PLUS evidence of end-organ damage — clinical (cold extremities, narrow pulse pressure, encephalopathy, oliguria), laboratory (metabolic acidosis, elevated lactate/creatinine/liver enzymes), or hemodynamic (CI <2.2 L/min/m2, PCWP >15 mmHg).

Important caveat: many CS patients fall outside these strict trial parameters — a patient can have SBP >90 mmHg and still have significant end-organ hypoperfusion; clinical judgment and hemodynamic/biomarker trend matter more than a rigid BP cutoff.

Mortality remains high: >40% in contemporary registries/trials.

2. SCAI Staging (5-tier, 2019, retrospectively validated against mortality)

SCAI stage identifies patients failing to respond or deteriorating and should trigger consideration of escalating support (Section 11).

3. Pathophysiology & Phenotyping

Reduced cardiac output -> systemic hypoperfusion + venous congestion -> a maladaptive spiral: compensatory vasoconstriction/tachycardia raises MAP but increases myocardial O2 demand -> worsens ischemia -> further impairs contractility -> rising filling pressures further compromise coronary perfusion pressure, especially as MAP falls. This vicious cycle is the core reason CS mortality remains high despite modern therapy.

Phenotype categorization (guides therapy and prognosis):

• Acute de novo CS (e.g., AMI, myocarditis, fulminant) vs CS complicating acute-on-chronic decompensated HF (~30% of all CS presentations, rising proportion)
• LV-predominant vs RV-predominant vs biventricular
• Pure cardiogenic vs mixed shock (e.g., concurrent sepsis/SIRS — "hemo-metabolic phase," reduced SVR complicating pure inotrope-based strategies)

Etiologies: AMI (most common acute cause), acute-on-chronic HF decompensation, myocarditis, valvular catastrophe (acute MR/AR, endocarditis), arrhythmia, post-cardiotomy, PE (RV-predominant), Takotsubo/stress cardiomyopathy, drug-induced (beta-blocker/CCB overdose).

4. Immediate Stabilization (ABCDE)

Airway/Breathing: oxygen/NIV/intubation as needed; be cautious — positive pressure ventilation and PEEP can decrease RV preload and increase RV afterload, worsening CO in preload-dependent CS; sedating induction agents can further impair RV preload and reduce SVR — choose hemodynamically neutral agents where possible for intubation.

Circulation — core management:

• Accurate volume status assessment is critical — unlike septic/hypovolemic shock, fluids are not the default first move; judicious fluid may help only if the patient is genuinely preload-deficient (left side of the Frank-Starling curve); excessive volume removal (diuresis) can precipitate hemodynamic collapse since these hearts are often highly preload-dependent
• First-line inotropes: dobutamine or milrinone (Class 1C recommendation for temporizing support) — both increase CO via enhanced contractility and vasodilation; use the lowest effective dose/duration given ischemia/arrhythmia risk; milrinone requires caution — longer half-life, can worsen hypotension, toxic metabolite accumulation with renal impairment
• First-line vasopressor: norepinephrine — raises MAP (salvaging coronary perfusion) and increases CO via venoconstriction-driven preload augmentation in a preload-responsive heart
• Epinephrine: alternative, but associated with higher rates of refractory shock compared to norepinephrine in comparative data
• Dopamine: combined inotrope/vasopressor; low-dose (0.5-2 mcg/kg/min) does NOT reliably improve renal perfusion despite historical belief — avoid relying on "renal-dose dopamine" as a strategy
• Acute-on-chronic decompensated HF-driven CS specifically: inotropes (dobutamine/milrinone) are first-line; use cautiously if SBP <80 or low filling pressures, favoring combination with norepinephrine/epinephrine to maintain BP while inotropes support CO; judicious diuresis targeting CVP 8-12 mmHg may improve ventricular-arterial coupling and reduce distension, but again, over-diuresis risks collapse in preload-dependent physiology; pure vasodilators (nitroprusside) can help in select patients with elevated SVR and SBP >100 mmHg by reducing afterload
• AMI-complicated CS may evolve a reduced-SVR "hemo-metabolic" phase (SIRS-like) where inotropes alone (which also vasodilate) are insufficient — recognize this phenotype shift and add vasopressor support accordingly

Disability/Exposure: standard assessment; monitor for evolving multi-organ dysfunction (hepatic congestion/shock liver, AKI) as downstream consequences of persistent low output.

Checklist:

5. Focused History

Chest pain/ACS symptoms, known HF history and baseline EF, recent viral illness (myocarditis), valvular disease history, recent cardiac surgery, arrhythmia history, medication history (beta-blocker/CCB overdose, negative inotropes), PE risk factors, peripartum timing (peripartum cardiomyopathy), family history of cardiomyopathy.

6. Examination + POCUS

Cold, clammy extremities, narrow pulse pressure, elevated JVP, S3, rales (LV-predominant) vs isolated elevated JVP without pulmonary edema (RV-predominant, e.g., inferior/posterior MI with RV involvement), new murmur (acute MR/AR, VSD), altered mentation, oliguria.

POCUS (central to phenotyping and monitoring): LV systolic function (global vs regional wall motion abnormality), RV size/function, valvular pathology (acute MR/AR, tamponade exclusion), IVC assessment, LVOT VTI for stroke volume trending, exclude tamponade/massive PE as alternate/co-existing obstructive causes (FALLS protocol integration — obstructive shock should be excluded before committing to a pure cardiogenic diagnosis).

7. Syndrome Identification

Confirm true cardiogenic (low CO, adequate-to-high filling pressures, low CI) rather than septic/mixed or obstructive shock via POCUS + invasive hemodynamics if available; identify LV vs RV vs biventricular predominance, as this changes fluid strategy and MCS device selection.

8. Differential Diagnosis

9. Investigations

• Bedside: ECG (STEMI/ischemia, arrhythmia), POCUS/formal echo, lactate
• Labs: troponin, BNP/NT-proBNP, renal/hepatic function (congestive hepatopathy/shock liver), CBC, coagulation
• Invasive hemodynamic monitoring: arterial line (continuous BP, waveform-derived SV/CO estimates); central venous catheter (CVP, ScvO2, waveform clues e.g. large CV wave in severe TR); pulmonary artery catheter (Swan-Ganz) — increasingly re-supported by observational data showing mortality benefit in CS, especially SCAI stage D/E, despite historical decline in PAC use; provides CI, PCWP, PAPi, cardiac power — key parameters for both diagnosis and serial monitoring of escalation/de-escalation decisions
• For AMI-CS: urgent coronary angiography

10. POCUS / Hemodynamic Parameters for Escalation Decisions

Favorable trend (consider de-escalation): CI >2.2 L/min/m2, cardiac power >0.6 W, PAPi >1.0, RAP <15 mmHg, PCWP <15 mmHg.

Refractory shock (consider MCS escalation): rising lactate, persistently low ScvO2, persistent hypotension, CI <2.2 L/min/m2, cardiac power <0.6 W — particularly in SCAI stage D/E patients.

11. Evidence-Based Management

Immediate: ECG + troponin to identify AMI-CS; if AMI-CS confirmed, urgent revascularization (PCI or CABG) improves outcomes — SHOCK trial demonstrated survival benefit with early revascularization; do not delay catheterization lab activation.

First hours: inotrope/vasopressor stabilization per Section 4; accurate volume assessment; triage/transfer to a Level 1 shock center capable of PCI, MCS, and cardiac surgery — delays in recognition or transfer contribute directly to mortality; a multidisciplinary "Shock Team" (cardiac intensivist, interventional cardiology, advanced HF, cardiothoracic surgery) has been shown in single-center studies to reduce in-hospital and 30-day mortality.

Escalation to temporary mechanical circulatory support (MCS) for SCAI D/E or refractory shock despite optimized medical therapy:

IABP mechanism: diastolic inflation augments coronary perfusion; systolic deflation reduces afterload and myocardial O2 demand — useful bridge-to-recovery (e.g., stunned myocardium) or bridge-to-decision.

Device selection driven by CS phenotype (LV vs RV vs biventricular) and degree of support needed; contraindications to any temporary MCS: poor vascular access (severe PAD), anoxic brain injury, end-stage multi-organ damage, misalignment with goals of care.

Decision to escalate to MCS should be multidisciplinary, weighing risk/benefit explicitly, ideally as bridge-to-recovery or bridge-to-more-durable-therapy (durable LVAD, transplant) rather than open-ended support.

12. Organ Support

Inotropes/vasopressors/MCS per above; mechanical ventilation with attention to hemodynamic effects of PEEP; renal replacement therapy for cardiorenal syndrome/refractory volume overload; nutrition and standard ICU supportive care once stabilizing.

13. Disease-Specific Therapy

AMI-CS: emergent revascularization (Section 11) is the single most important disease-modifying intervention. Acute-on-chronic HF-CS: guideline-directed medical therapy resumption once stabilized (beta-blocker, ACEi/ARNI, MRA, SGLT2i per standard HF guidelines, introduced cautiously during recovery phase, not during active shock).

14. Consultation Matrix

15. Monitoring Framework

Continuous arterial pressure monitoring, serial lactate/ScvO2, serial echo/POCUS for CI and RV/LV function trend, PAC-derived hemodynamics if placed, daily reassessment against escalation/de-escalation criteria (Section 10), vigilance for MCS device-specific complications (limb ischemia, hemolysis, bleeding, infection).

16. ICU Bundle Checklist (Daily)

17. Complications

Progressive multiorgan failure (cardiorenal/cardiohepatic syndrome), arrhythmia, MCS device complications (limb ischemia, hemolysis, bleeding, vascular injury, infection), recurrent ischemia from inotrope-driven myocardial O2 demand, ventricular arrhythmia. Prevention: lowest effective inotrope dosing, careful volume management, device-specific vascular access technique and surveillance. Rescue: device exchange/escalation (e.g., IABP to Impella to VA-ECMO) per multidisciplinary Shock Team decision, surgical repair for mechanical complications.

18. Escalation & De-escalation

Escalate: SCAI stage worsening, refractory hemodynamic parameters (Section 10) despite optimized inotrope/vasopressor therapy -> MCS.

De-escalate: favorable hemodynamic trend (Section 10) -> trial weaning inotropes/vasopressors/MCS support, transition to guideline-directed HF therapy once stable.

Palliation pathway: for patients with SCAI E physiology not responding to maximal support, or where MCS/escalation is not aligned with goals of care — explicit multidisciplinary discussion including palliative care.

19. ICU Discharge Criteria

Hemodynamically stable off/on minimal inotropic support, MCS weaned or transitioned to a durable/outpatient-compatible device, guideline-directed HF therapy initiated as tolerated, underlying cause addressed (revascularized, myocarditis treated, etc.), renal/hepatic function stable or improving.

20. Documentation & Medicolegal Checklist

21. Key Guidelines

American Heart Association Scientific Statements: "Invasive Management of AMI Complicated by Cardiogenic Shock" (Henry et al., Circulation 2021) and "Escalating and De-escalating Temporary Mechanical Circulatory Support in Cardiogenic Shock" (Geller et al., Circulation 2022); SCAI Shock Classification (2019).

22. Landmark Trials

• SHOCK trial (Hochman et al., 1999): early revascularization in AMI-CS improved 6-month survival — foundational trial establishing urgent revascularization as standard of care.
• Registry/observational data (National Inpatient Sample, 10-year retrospective) showing 9% mortality reduction with PAC use in CS — renewed interest in invasive hemodynamic monitoring despite earlier era's move away from routine PAC use.
• Meta-analyses of percutaneous LVAD (Impella-type) vs IABP — mixed results, no definitive mortality benefit established for one MCS modality over another across all CS phenotypes; device selection remains individualized (see Controversies).

23. Controversies

Despite widespread use, there is a lack of high-quality RCT evidence guiding the initial choice among inotropes/vasopressors in CS — current practice is guided more by physiologic reasoning and observational/registry data than head-to-head trials, and heterogeneity in trial populations/designs limits what evidence does exist. Optimal MCS device selection and timing (early/proactive vs reserved for refractory shock) remains debated and center-dependent; no single device has demonstrated clear superiority across all phenotypes. PAC/Swan-Ganz use has seen a resurgence in CS management specifically despite a broader historical decline in ICU use, reflecting evolving, somewhat unsettled practice patterns. The threshold for escalation to VA-ECMO vs percutaneous LVAD devices as first-tier MCS varies substantially by institutional experience and resource availability rather than a single evidence-based algorithm.

24. References

1. Lick AN, May AM, Schilling JD. Cardiogenic Shock. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 4).
2. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock (SHOCK trial). N Engl J Med. 1999;341(9):625-634.
3. Henry TD, Tomey MI, Tamis-Holland JE, et al. Invasive management of acute myocardial infarction complicated by cardiogenic shock: AHA scientific statement. Circulation. 2021;143(15):e815-e829.
4. Geller BJ, Sinha SS, Kapur NK, et al. Escalating and de-escalating temporary mechanical circulatory support in cardiogenic shock: AHA scientific statement. Circulation. 2022;146(6):e50-e68.
5. Baran DA, Grines CL, Bailey S, et al. SCAI clinical expert consensus statement on the classification of cardiogenic shock. Catheter Cardiovasc Interv. 2019;94(1):29-37.
6. Cheng JM, den Uil CA, Hoeks SE, et al. Percutaneous LVADs vs IABP for cardiogenic shock: meta-analysis. Eur Heart J. 2009;30(17):2102-2108.